A Case of Diffuse Alveolar Hemorrhage Following Abciximab Therapy.
- Author:
Han Jun RYU
1
;
Yeoun Su JUNG
;
Min Hee KIM
;
Ho Jin JUNG
;
Byung Chun JUNG
;
Bong Ryeol LEE
;
Hyun Jae KANG
Author Information
1. Department of Internal Medicine, Daegu Fatima Hospital, Daegu, Korea. tangul8845@hanmail.net
- Publication Type:Case Report
- Keywords:
Acute coronary syndrome;
Hemoptysis
- MeSH:
Acute Coronary Syndrome;
Antibodies, Monoclonal;
Blood Platelets;
Glycoproteins;
Hemoptysis;
Hemorrhage;
Immunoglobulin Fab Fragments;
Percutaneous Coronary Intervention
- From:Korean Journal of Medicine
2013;84(4):562-566
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Platelets play an important role in the development of acute coronary syndrome. Platelet-inhibiting drugs, such as glycoprotein IIb/IIIa inhibitors, can be beneficial when they are administered at the time of primary percutaneous coronary intervention for acute coronary syndrome. Although an increased risk for bleeding complications is well recognized, the risk associated with diffuse alveolar hemorrhage is much less reported. We report a case of diffuse alveolar hemorrhage after using abciximab.
